SAN DIEGO, Dec. 19, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that
Amit D. Munshi, the Company's
President and Chief Executive Officer, will present a corporate
update at the 37th Annual J.P. Morgan Healthcare Conference on
Thursday, January 10, 2019 at
8:30 AM PST. The conference will take
place January 7-10, 2019 at the
Westin St. Francis Hotel in San
Francisco.
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology and pharmacokinetics to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility.
Etrasimod (APD334), with potential utility in a broad range of
immune and inflammatory conditions, is being evaluated in
later-stage clinical programs in ulcerative colitis (UC) and
Crohn's disease, as well as in programs for primary biliary
cholangitis (PBC) and atopic dermatitis. Ralinepag (APD811) is
being evaluated in a Phase 3 program for pulmonary arterial
hypertension (PAH). Arena is also evaluating olorinab (APD371) in a
Phase 2 program for gastrointestinal pain. Arena continues to
assess other earlier research and development stage drug
candidates, including APD418 for decompensated heart failure.
In addition, Arena has several partnerships including with
Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries),
Boehringer Ingelheim International GmbH (undisclosed target -
preclinical), Outpost Medicine, LLC (undisclosed target –
preclinical), and Eisai Co., Ltd. and Eisai Inc.
(BELVIQ® - marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "will," "driven to," "potentially,"
"potential," or words of similar meaning, or they may be identified
by the fact that they do not relate strictly to historical or
current facts. Such forward-looking statements include, without
limitation, statements about Arena's drive, focus, goals, strategy,
clinical and research and development programs, and collaborations.
For such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking
statements include the closing of Arena's announced licensing
agreement with United Therapeutics regarding ralinepag, which is
subject to regulatory approval and other conditions; the
timing and outcome of research, development and regulatory review
is uncertain; clinical programs may not proceed at the time or in
the manner expected or at all; results of clinical trials and other
studies are subject to different interpretations and may not be
predictive of future results; and other risks related to developing
and commercializing drugs; as well as those factors disclosed in
Arena's filings with the Securities and Exchange
Commission (SEC), including but not limited to Arena's
Quarterly Report on Form 10-Q for the quarter ended September
30, 2018, which was filed with the SEC on November
8, 2018. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-37th-annual-jp-morgan-healthcare-conference-on-january-10-300768611.html
SOURCE Arena Pharmaceuticals, Inc.